• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗血管内皮生长因子治疗糖尿病黄斑水肿对神经节细胞层囊肿的影响。

The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.

机构信息

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Bern Photographic Reading Center, University Hospital Bern, Bern, Switzerland.

出版信息

Acta Ophthalmol. 2019 Dec;97(8):e1041-e1047. doi: 10.1111/aos.14137. Epub 2019 May 17.

DOI:10.1111/aos.14137
PMID:31099498
Abstract

PURPOSE

To investigate the prevalence and impact of ganglion cell layer cysts (GCLC) in patients with diabetic macular oedema (DME) under continuous anti-vascular endothelial growth factor (VEGF) therapy.

METHODS

The clinical findings and spectral domain optical coherence devices of baseline visits and follow-up after 12-24 and 36 months of DME patients under continuous anti-VEGF therapy were retrospectively collected and analysed for the impact of GCLC cysts. Previously established prognostic parameters were also assessed.

RESULTS

A total of 110 eyes of 110 DME patients (mean age 64 ± 10 years) were included. At baseline, 17% eyes had GCLC. With GCLC, the best-corrected visual acuity (BCVA) improvement was in mean 8.4 ± 2.4 Early-Treatment-Diabetic-Retinopathy-Study (ETDRS) letters less over the course of 36 months compared to the group lacking GCLC (p = 0.0009). Eyes with GCLC showed 68 ± 23.4 μm less central retinal thickness (CRT) decrease than eyes lacking GCLC (p < 0.0001). In the linear mixed effect models including external limiting membrane disruption, disintegration of inner retinal layer and epiretinal membrane, GCLC remained a statistical significant factor for the outcome parameter CRT, but missed statistical significance for BCVA.

CONCLUSION

Ganglion cell layer cysts (GCLC) seem to impact outcome in DME in patients receiving long-term treatment. This prognostic factor warrants further evaluation in the context of already well-established outcome parameters.

摘要

目的

研究在接受抗血管内皮生长因子(VEGF)治疗的糖尿病黄斑水肿(DME)患者中,神经节细胞层囊肿(GCLC)的发生率及其影响。

方法

回顾性收集了连续接受抗 VEGF 治疗的 DME 患者的基线检查、治疗后 12-24 个月和 36 个月的临床发现和频域光学相干断层扫描(OCT)结果,分析 GCLC 囊肿对患者的影响。同时还评估了先前建立的预测参数。

结果

共纳入 110 例 110 只眼 DME 患者(平均年龄 64±10 岁)。基线时,17%的眼存在 GCLC。与无 GCLC 的患者相比,有 GCLC 的患者在 36 个月的治疗过程中最佳矫正视力(BCVA)平均提高了 8.4±2.4 个早期治疗糖尿病性视网膜病变研究(ETDRS)字母(p=0.0009)。有 GCLC 的眼比无 GCLC 的眼中央视网膜厚度(CRT)减少了 68±23.4μm(p<0.0001)。在包括外部限制膜破裂、内视网膜层分离和视网膜前膜的线性混合效应模型中,GCLC 仍然是 CRT 这一结果参数的统计学显著因素,但在 BCVA 这一参数中失去了统计学意义。

结论

在接受长期治疗的 DME 患者中,神经节细胞层囊肿(GCLC)似乎会影响治疗效果。这一预测因素在已有成熟的预后参数的基础上,值得进一步评估。

相似文献

1
The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.抗血管内皮生长因子治疗糖尿病黄斑水肿对神经节细胞层囊肿的影响。
Acta Ophthalmol. 2019 Dec;97(8):e1041-e1047. doi: 10.1111/aos.14137. Epub 2019 May 17.
2
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.长期玻璃体内抗血管内皮生长因子治疗对糖尿病性黄斑水肿中预先存在的微观结构改变的影响。
Retina. 2018 Sep;38(9):1824-1829. doi: 10.1097/IAE.0000000000001788.
3
Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.丹麦国家指南指导下,566 例糖尿病黄斑水肿患者接受玻璃体腔抗血管内皮生长因子治疗:2-4 年视力和视网膜厚度随访结果。
Acta Ophthalmol. 2018 May;96(3):267-278. doi: 10.1111/aos.13638. Epub 2017 Dec 14.
4
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.持续给予瑞巴派特与添加地塞米松治疗持续性糖尿病黄斑水肿患者的效果:DRCR 网络的一项 2 期随机临床试验。
JAMA Ophthalmol. 2018 Jan 1;136(1):29-38. doi: 10.1001/jamaophthalmol.2017.4914.
5
One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.在初治糖尿病性黄斑水肿患者中使用无负荷期的抗VEGF药物治疗并延长方案的一年结果
Ophthalmologica. 2019;241(4):220-225. doi: 10.1159/000495623. Epub 2019 Jan 17.
6
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.糖尿病性黄斑水肿抗血管内皮生长因子比较有效性试验:一项随机临床试验的额外疗效事后分析
JAMA Ophthalmol. 2016 Dec 1;134(12). doi: 10.1001/jamaophthalmol.2016.3698.
7
MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.光学相干断层扫描渗漏测量在糖尿病性黄斑水肿中的应用:视力反应治疗的生物标志物。
Retina. 2019 Jan;39(1):52-60. doi: 10.1097/IAE.0000000000001905.
8
Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.抗血管内皮生长因子治疗糖尿病黄斑水肿后脉络膜厚度的变化,真实世界数据,2 年结果。
Cutan Ocul Toxicol. 2021 Dec;40(4):326-331. doi: 10.1080/15569527.2021.1949338. Epub 2021 Jul 19.
9
COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.糖尿病性黄斑水肿患者在日常实践中接受玻璃体内抗血管内皮生长因子治疗的依从性和顺应性。
Retina. 2018 Dec;38(12):2293-2300. doi: 10.1097/IAE.0000000000001892.
10
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.阿柏西普用于曾接受雷珠单抗和/或贝伐单抗治疗的糖尿病性黄斑水肿眼,可能会进一步改善黄斑厚度。
Ophthalmic Surg Lasers Imaging Retina. 2016 Sep 1;47(9):836-9. doi: 10.3928/23258160-20160901-06.

引用本文的文献

1
Sustained Benefit of Short-Term Levodopa Treatment on Inner Retinal Function in Patients With Diabetes.短期左旋多巴治疗对糖尿病患者视网膜内层功能的持续益处。
Transl Vis Sci Technol. 2025 Sep 2;14(9):5. doi: 10.1167/tvst.14.9.5.
2
Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies.用于预测视网膜静脉阻塞相关性黄斑水肿治疗反应的光学相干断层扫描、多模态成像和细胞因子标志物的综合评估:抗血管内皮生长因子和类固醇疗法的比较性综述
Diagnostics (Basel). 2024 Sep 7;14(17):1983. doi: 10.3390/diagnostics14171983.
3
Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review.
玻璃体内抗血管内皮生长因子治疗糖尿病性黄斑水肿后改用玻璃体内地塞米松植入物:综述
Life (Basel). 2024 Jun 3;14(6):725. doi: 10.3390/life14060725.
4
The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers.玻璃体内皮质类固醇在 DME 治疗中的作用:预测性 OCT 生物标志物。
Int J Mol Sci. 2022 Jul 8;23(14):7585. doi: 10.3390/ijms23147585.
5
Comparing Objective Perimetry, Matrix Perimetry, and Regional Retinal Thickness in Mild Diabetic Macular Edema.比较客观视野计、矩阵视野计和轻度糖尿病性黄斑水肿的局部视网膜厚度。
Transl Vis Sci Technol. 2021 Nov 1;10(13):32. doi: 10.1167/tvst.10.13.32.